Vergent Bioscience

Vergent Bioscience is a clinical-stage biotechnology company developing tumor-targeted imaging agents. It is creating a molecularly targeted probe that binds to enzymes overexpressed in tumor tissues, activating a bright fluorescent dye. This makes the cancer "light up," providing surgeons with clear visual guidance for the removal of tumors and associated metastases. Vergent’s proprietary probes are being developed for use in multiple cancers, including lung, breast, ovarian, colorectal, and brain cancer. Vergent aims to enable surgeons to see previously undetected or hard-to-find tumors in real-time during surgery, ensuring all tumor tissue is removed. The company is initially evaluating VGT-309 for use in lung cancer, with the potential to expand its application to a broad range of solid tumors.